vaccine. In the 27 years since publication almost 1 million newborns were congenitally infected in the USA and over 100,000 were significantly affected by their infection including neurologic disabilities, developmental delays and most commonly sensorial hearing deficits. In 2000 the Institute of Medicine reported that a cytomegalovirus (CMV) vaccine had the highest priority based on cost savings (1) . Yet, it is now 2016 and the availability of a CMV vaccine is at least 6-10 years away. It is clear that part of the problem lies in the public perception and lack of awareness of CMV (2, 3) . Trying to shed light on this perception some have asked; What if CMV caused a rash (4) or What if CMV was transmitted by a mosquito (5).
In 2000, a U.S. Government-sponsored meeting proposed activities to support CMV vaccine development within the disciplines of virology, immunology, epidemiology, and clinical trial (6) . More recently, in 2012, representatives from government, industry, academia, patient advocacy groups, and professional societies met and provided further impetus to the field by identifying and beginning to address challenges to CMV vaccine development (7) . Participants discussed optimal uses of a CMV vaccine, aspects of clinical study design, and the need for additional research in specified areas. It was suggested that clinical trials of CMV vaccines in women should evaluate protection against congenital CMV (cCMV) infection, an essential precursor of cCMV disease.
Thus, although the goal of a cCMV vaccine is to prevent disease, the infection endpoint was felt to be a more practical and acceptable endpoint for assessing vaccine effects on maternal-fetal transmission. Never the less trials will require more participants and more complexity than usual.
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The other recent impetus to the development of a CMV vaccine for cCMV was the result of recent trials evaluating a glycoprotein B (gB) sub unit vaccine adjuvanted with MF-59 (Sanofi Pasteur). gB, the major surface glycoprotein, was chosen as it is a major target for CMV neutralizing antibodies and MF-59 was selected as the adjuvant because it boosts antibody levels. The first trial showed a significant reduction in the infection rate of vaccinated women compared to the placebo group of about 50% (8) while the second showed about a 40% reduction in young women that was not significant (9) . Both used infection of the participants identified by seroconversion and/or detection of virus as the endpoint. Other trials of a different gB vaccines (GlaxoSmithKline and VBI) are also underway (clinical trials.gov, NCT00435396, NCT02826798, respectively).
Other phase 1 safety and immunogenicity studies have evaluated gB and pp 65 expressed in alpha virus replicons (10) . The phosphoprotein, PP65, was selected because it is the principal target of CMV-specific CD8 + CTL responses. These studies showed this approach was safe and immunogenic inducing both antibody and T cells. (17) and the guinea pig homologs of gB and pp65. As CMV is highly species specific only the corresponding CMV strain can be used in animal evaluations. The guinea pig is considered the best small animal model because the guinea pig has a hemomonochorial placenta similar to humans that allows CMV to cross the placental and infect the pups causing morbidity including hearing loss and mortality depending on the challenge dose and timing of the challenge (18) .
Similar rLCMV vaccines were initially evaluated by Cardin et al (19) . In their study the rLCMV-gB vaccine significantly improved pup survival and also increased pup weights and gestation time. The gB vaccine was also more effective at decreasing viral load in dams and pups and limiting congenital transmission than the control or the rLCMV- in the bivalent preparation but did not decrease infection rates (50% in control group vs.
53% in bivalent). Perhaps the lack of decrease in infection can be partially explained by the differences in the rate of identification of CMV in live and dead pups that were available from the groups to determine infection. Decreasing the infection rate is important as this may be the end point in phase 3 clinical trials (7) and sequelae from congenital infections can occur years after birth (20). As a comparison, the mortality in the gB subunit vaccine control was 20% and the infection rate 55%. Vaccination also decreased the maternal virus load and improved the duration of the pregnancy. In most comparisons the bivalent vaccine was superior to either of the monovalent vaccines.
Thus, the results from 2 preclinical studies of the rLCMV vectored approach for cCMV were encouraging and similar to other preclinical studies of subunit gB vaccines (21) (22) (23) , that are comparable to those used in the moderately successful human trials (8, 9) .
Besides gB, there is considerable interest in adding proteins from the pentameric complex of CMV to enhance and extend neutralizing antibody (24) . Because preventing infection is so important it is not clear whether vaccines tested to date in this model should proceed to human trials or whether further evaluations are necessary. Perhaps future refinements in the evaluation of CMV vaccines could include the use of nonhuman primates (25, 26) and mucosal administration of the challenge inoculum to better mimic natural infection.
Better times for CMV vaccines are here hopefully good times to follow. 
